Ponatinib Tablets Ponaxen 15mg are a specialized pharmaceutical formulation designed for the targeted treatment of chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). The active ingredient, Ponatinib, belongs to a class of drugs known as tyrosine kinase inhibitors (TKIs), which precisely block abnormal proteins involved in the proliferation of leukemic cells. This precision in targeting cancer cells helps in controlling disease progression, particularly in cases resistant to other therapies. Ponaxen 15mg tablets are manufactured following strict quality assurance protocols to maintain high efficacy and safety. The dosage and duration of treatment are tailored individually by healthcare providers to optimize therapeutic outcomes while minimizing potential adverse effects. Healthcare professionals supply the tablets with guidance on monitoring for side effects, ensuring patient adherence to treatment plans. Ponaxen 15mg provides an advanced medicinal option for oncology specialists managing aggressive or resistant leukemia cases.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Ponatinib |
| Dosage Strength | 15 mg per tablet |
| Therapeutic Class | Tyrosine Kinase Inhibitor |
| Indications | Chronic Myeloid Leukemia (CML), Acute Lymphoblastic Leukemia (ALL) |
| Formulation | Oral Tablets |
| Packaging | Bottled with a specified number of tablets |
| Manufacturer Quality | Produced under stringent quality standards ensuring efficacy and safety |
| Administration | Oral, with dosage prescribed by a healthcare provider |
| Monitoring and Safety | Requires regular monitoring for side effects as advised by physician |
| Target Mechanism | Inhibits protein tyrosine kinases responsible for cancer cell growth |
| Attributes | Description |
|---|---|
| Drug Class | Tyrosine Kinase Inhibitor (TKI) |
| Chemical Name | Ponatinib |
| Strength | 15 mg |
| Dosage Form | Tablet |
| Route of Administration | Oral |
| Therapeutic Uses | Treatment of CML and Philadelphia chromosome-positive ALL |
| Storage Conditions | Store in a cool, dry place away from direct sunlight |
| Shelf Life | As per manufacturer’s label |
| Prescription Requirement | Prescription Only Medicine (POM) |
| Side Effects Monitoring | Essential to report adverse reactions immediately to healthcare provider |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
Ponatinib Tablets Ponaxen 15mg are prescribed specifically for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL).
Ponatinib works by inhibiting tyrosine kinase enzymes that are responsible for cancer cell growth and proliferation, thereby blocking the progression of leukemia.
Ponaxen 15mg is intended for patients diagnosed with CML or ALL who require treatment with Ponatinib, typically when resistance or intolerance to prior therapies is observed. Patient suitability must be assessed by a healthcare professional.
Patients must follow doctor’s instructions closely, monitor for side effects such as cardiovascular events or liver dysfunction, and report any adverse symptoms immediately for optimal safety.
Ponaxen tablets should be stored in a cool, dry place away from direct sunlight and moisture to maintain stability and effectiveness.
Inclusive of all taxes
You Save: 0
Bengaluru , India
Retailer, Brand Owner, Distributor, Exporter, Importer, Wholesaler
GST- 29AQTPJ8785C1Z2
